BioBlast Pharma is a publicly traded, clinical-stage biotechnology company (NASDAQ ? ?ORPN?). Developing safe and effective therapies for rare genetic diseases. Bioblast Pharma (NASDAQ: ORPN), is a clinical-stage biotechnology company built on the premise of discovering, developing, and delivering clinically meaningful therapies for patients with rare diseases.
BioBlast Pharma is Tel Aviv, Israel based company founded by Colin Foster, Dr. Dalia Megiddo and Udi Gilboa focuses on building a diverse portfolio of product candidates with the potential to address unmet medical need for incurable rare diseases.